|
| Reference | Patients | Serum ANGPTL2 (ng/ml) | ELISA kit | Conclusion of the study |
|
| [48] | Chronic kidney disease (stage 5) ± kidney transplant, Canada | from 71 [53–95] to 11 [9–15] after kidney transplant | USCN Life Science Inc., China | High ANGPTL2 after kidney transplant is associated with aortic stiffness, pulse pressure, renal function, and mortality. |
| [44] | Hisayama study, general population, Japan | Q1: <2.2
Q4: >3.4 | IBL, Japan | High ANGPTL2 is an independent factor for T2DM development. |
| [50] | Coronary artery disease versus age-matched controls, Canada | ~6.0 versus 1.0 in controls | USCN Life Science Inc., China | ANGPTL2 promotes atherosclerosis in mice.
ANGPTL2 is higher in CAD patients. |
| [45] | Diabetes and chronic kidney disease (<stage 4), France | Q1: <11.2
Q4: >19.5 | USCN Life Science Inc., China | ANGPTL2 improves risk stratification inT2DM: Q4 predicts MACE and mortality. |
| [51] | Hisayama study, general Japanese population | Q1: <2.25
Q4: >3.62 | IBL, Japan | High ANGPTL2 is an independent factor for cardiovascular disease development. |
| [26] | Coronary heart disease versus controls, Japan | ~4.6 versus 3.6 in controls | IBL, Japan | ANGPTL2 is higher in coronary heart disease patients. |
| Seniors (85–99 years old), general population, Japan | 4.1 [3.2–5.1] | | ANGPTL2 correlates with inflammation, IMT, and the presence of plaque: ANGPTL2 reflects atherosclerosis. |
| [52] | Heart failure versus age-matched controls, Taiwan | ~4.6 versus 3.5 in controls
T1: <3.4
T3: >4.8 | IBL, Japan | ANGPTL2 is higher in HF patients. Higher risk (2.97-fold) of HF in patients with ANGPTL2 levels in T3. |
| [53] | T2DM, South Korea | Q1: <3.3
Q4: >5.2 | IBL, Japan | ANGPTL2 correlates with carotid IMT: ANGPTL2 is important in atherosclerosis. |
| [7] | Coronary artery disease versus age-matched controls, Canada | ~5.5 versus 2.0 in controls | USCN Life Science Inc., China | ANGPTL2 is higher in CAD patients.
Acute intermittent exercise reduces ANGPTL2. |
| [46] | Diabetes with nephropathy versus controls, China | 36.1 to 50.2 versus 24.0 in controls | USCN Life Science Inc., China | ANGPTL2 is independently associated with albuminuria: role of ANGPTL2 in nephropathy in T2DM patients. |
| [58] | Obese metabolically healthy women China | 4.2 (at risk for insulin resistance) versus 2.9 (normal IS) | Not mentioned | ANGPTL2 is negatively correlated with insulin sensitivity and serum epinephrine levels. |
| [59] | Overweight healthy men, Japan | ~3.0 versus 2.8 after diet and exercise | IBL, Japan | Lifestyle intervention reduces ANGPTL2.
Changes in ANGPTL2 reflect visceral fat and metabolic improvement. |
| [54] | Acute coronary syndrome versus age-matched controls, Canada | ~3.4 versus 1.8 in controls | USCN Life Science Inc., China | ANGPTL2 is higher in acute coronary syndrome patients and is associated with reduced leukocyte DNA methylation in the promoter region of ANGPTL2 gene. |
| [55] | Coronary artery disease versus controls, Japan | ~4.0–6.7 versus 3.0 in controls | IBL, Japan | ANGPTL2 is higher in patients with multivessel CAD than in those with single vessel disease. |
| [60] | Severe obese ± bariatric surgery, Canada | 12.3 (9.3–14.9) | USCN Life Science Inc., China | Bariatric surgery decreases ANGPTL2 and this is associated with a better cardiometabolic profile, not with anthropometric parameters. |
| [77] | Patients with acute myocardial infarction, Japan | ~2.0 | IBL, Japan | Statin started early after the onset of myocardial infarction reduces ANGPTL2. |
| [5] | Coronary artery disease, obese, diabetes versus controls, Japan | ~4.0–5.0 versus 2.5 in controls | IBL, Japan | ANGPTL2 is a key adipocyte-derived inflammatory mediator that links obesity to insulin resistance. |
| [8] | Post-acute coronary syndrome patients, effect of exercise, Canada | Men: from 2.8 to 1.4 after EX
Women: from 4.4 to 5.1 after EX | USCN Life Science Inc., China | In post ACS men (not women), ANGPTL2 is reduced by exercise training. ANGPTL2 reached at the end of the training reflects endothelial and cardiopulmonary functions. |
| [68] | Dilated cardiomyopathy, Japan | Coronary sinus: 4.6 versus 2.1
Aortic root: 2.4 versus 2.5 | IBL, Japan | A difference between ANGPTL2 in coronary sinus and aortic root reflects ANGPTL2 secretion from the heart. |
| [9] | Hisayama study, general population, Japan | Q1: 2.0
Q4: >3.7 | IBL, Japan | High ANGPTL2 is associated with the prevalence of chronic kidney disease. |
| [57] | Acute coronary syndrome versus controls, China | Q1: <11.3
Q4: >43.7
versus 7–25 in controls | Cusabio, China | ANGPTL2 is closely associated with ACS and provides risk stratification of the disease. |
| [47] | Gestational diabetes, China | Q1: <2.0
Q4: >3.5 | IBL, Japan | ANGPTL2 is higher in women with gestational diabetes. The risk of developing gestational diabetes is x2.9 in Q4. |
|
